TEST BANK
Goodman and Gilman's The
Pharmacological Basis of Therapeutics
14th Edition
Author(s)Laurence Brunton; Bjorn Knollmann
Print ISBN: 9781264258079
,Question 1
A research team isolates a previously uncharacterized alkaloid from a
medicinal plant and finds that it produces a reproducible biological
effect in a validated cell-based assay. Which finding would most strongly
support advancing the compound as a drug-discovery lead?
A. The compound is abundant in the plant extract
B. The compound produces a reproducible, concentration-dependent
,effect in the assay
C. The compound has a long history of traditional use
D. The compound is chemically unlike all currently marketed drugs
Correct Answer:
B. The compound produces a reproducible, concentration-dependent
effect in the assay
Rationale:
A reproducible, concentration-dependent biological effect provides
direct experimental evidence that the compound has measurable
pharmacological activity and can serve as a starting point for further
characterization and optimization. A high natural abundance may
facilitate isolation but does not establish efficacy. Traditional use can
generate useful hypotheses but does not substitute for experimental
evidence. Chemical novelty may be desirable, but novelty alone does
not demonstrate useful biological activity.
Question 2
During early drug discovery, investigators identify a molecule that
interacts with a desired biological target but has poor potency and
limited selectivity. What is the most appropriate interpretation of this
molecule?
A. It is automatically a viable clinical candidate
B. It is a lead that may require further optimization
C. It should be discarded because only potent compounds are useful
D. It is already a validated therapeutic agent
, Correct Answer:
B. It is a lead that may require further optimization
Rationale:
A lead compound has sufficient biological or chemical interest to justify
optimization, but it is not necessarily ready for clinical development.
Medicinal chemistry can modify potency, selectivity, physicochemical
properties, and pharmacokinetic behavior. Poor potency does not
automatically eliminate a compound if the underlying chemical scaffold
and mechanism are promising. Clinical candidacy requires substantially
broader evidence than target interaction alone.
Question 3
A medicinal chemist systematically changes one substituent on a lead
compound and observes that small structural modifications produce
predictable changes in potency. Which concept is being used?
A. Structure-activity relationship analysis
B. First-pass metabolism
C. Therapeutic drug monitoring
D. Pharmacovigilance
Correct Answer:
A. Structure-activity relationship analysis
Rationale:
Structure-activity relationship (SAR) analysis examines how chemical
structural changes influence biological activity. By comparing related
analogues, investigators can identify structural features associated with
potency, selectivity, and other desirable properties. First-pass
Goodman and Gilman's The
Pharmacological Basis of Therapeutics
14th Edition
Author(s)Laurence Brunton; Bjorn Knollmann
Print ISBN: 9781264258079
,Question 1
A research team isolates a previously uncharacterized alkaloid from a
medicinal plant and finds that it produces a reproducible biological
effect in a validated cell-based assay. Which finding would most strongly
support advancing the compound as a drug-discovery lead?
A. The compound is abundant in the plant extract
B. The compound produces a reproducible, concentration-dependent
,effect in the assay
C. The compound has a long history of traditional use
D. The compound is chemically unlike all currently marketed drugs
Correct Answer:
B. The compound produces a reproducible, concentration-dependent
effect in the assay
Rationale:
A reproducible, concentration-dependent biological effect provides
direct experimental evidence that the compound has measurable
pharmacological activity and can serve as a starting point for further
characterization and optimization. A high natural abundance may
facilitate isolation but does not establish efficacy. Traditional use can
generate useful hypotheses but does not substitute for experimental
evidence. Chemical novelty may be desirable, but novelty alone does
not demonstrate useful biological activity.
Question 2
During early drug discovery, investigators identify a molecule that
interacts with a desired biological target but has poor potency and
limited selectivity. What is the most appropriate interpretation of this
molecule?
A. It is automatically a viable clinical candidate
B. It is a lead that may require further optimization
C. It should be discarded because only potent compounds are useful
D. It is already a validated therapeutic agent
, Correct Answer:
B. It is a lead that may require further optimization
Rationale:
A lead compound has sufficient biological or chemical interest to justify
optimization, but it is not necessarily ready for clinical development.
Medicinal chemistry can modify potency, selectivity, physicochemical
properties, and pharmacokinetic behavior. Poor potency does not
automatically eliminate a compound if the underlying chemical scaffold
and mechanism are promising. Clinical candidacy requires substantially
broader evidence than target interaction alone.
Question 3
A medicinal chemist systematically changes one substituent on a lead
compound and observes that small structural modifications produce
predictable changes in potency. Which concept is being used?
A. Structure-activity relationship analysis
B. First-pass metabolism
C. Therapeutic drug monitoring
D. Pharmacovigilance
Correct Answer:
A. Structure-activity relationship analysis
Rationale:
Structure-activity relationship (SAR) analysis examines how chemical
structural changes influence biological activity. By comparing related
analogues, investigators can identify structural features associated with
potency, selectivity, and other desirable properties. First-pass
